Dalrada Financial Corporation Healthcare Subsidiary, Genefic, Inc., Acquires IV Services Infusion Pharmacy
May 21, 2024 08:45 ET
|
Dalrada Financial Corp.
Company enters $42 billion marketplace with acquisition of established and successful infusion pharmacy.
Aerami Therapeutics Presents New Lung Deposition Modeling Data For AER-901 in Pulmonary Hypertension at the American Thoracic Society 2024 International Conference
May 20, 2024 17:00 ET
|
Aerami Therapeutics Inc
DURHAM, N.C., May 20, 2024 (GLOBE NEWSWIRE) -- Aerami Therapeutics (“Aerami”), a clinical stage biopharmaceutical company dedicated to breathing life into the treatment of serious and rare...
Sanofi: Informations relatives au nombre de droits de vote et d'actions - Avril 2024
May 20, 2024 16:54 ET
|
Sanofi - Aventis Groupe
Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L. 233-8 II du Code de commerce et l’article 223-16 du Règlement général de l’Autorité des Marchés...
Sanofi: Information concerning the total number of voting rights and shares - April 2024
May 20, 2024 16:54 ET
|
Sanofi - Aventis Groupe
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement...
Lumos Pharma Announces Abstracts Accepted for Presentation at ENDO 2024
May 20, 2024 16:05 ET
|
Lumos Pharma, Inc.
AUSTIN, Texas, May 20, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, announced today that new...
More than $9 Million Awarded to High School Scientists and Engineers at the Regeneron International Science and Engineering Fair 2024
May 17, 2024 13:45 ET
|
Regeneron Pharmaceuticals, Inc.
TARRYTOWN, N.Y. and WASHINGTON, D.C., May 17, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Society for Science (the Society) announced that Grace Sun, 16, of...
Phathom Pharmaceuticals to Present VOQUEZNA® (vonoprazan) Data at DDW 2024 Annual Meeting
May 15, 2024 08:00 ET
|
Phathom Pharmaceuticals
First oral presentation of Phase 3 data evaluating the investigational use of VOQUEZNA® in Non-Erosive Reflux Disease (NERD)1New research on Erosive gastroesophageal reflux disease (GERD)...
atai Life Sciences Reports First Quarter 2024 Financial Results and Corporate Updates
May 15, 2024 06:59 ET
|
atai Life Sciences
First participant dosed in Phase 1b trial of VLS-01 with data expected in 2H’24; Phase 2 study in TRD patients anticipated to initiate around YE’24Beckley Psytech’s Phase 2a study of BPL-003 in TRD...
Lumos Pharma Announces Positive End-of-Phase 2 Meeting with FDA and Reports First Quarter 2024 Financial Results
May 14, 2024 16:15 ET
|
Lumos Pharma, Inc.
Outcome from End-of-Phase 2 Meeting Supportive of a Placebo-Controlled Phase 3 Trial Updated 12 and 24-Month Data from Phase 2 OraGrowtH210 and OraGrowtH212 Trials Continue to Show Oral LUM-201...
Global Iron Drugs Strategic Business Report 2024: Market to Reach $11 Billion by 2030 with Oral Segment to Account for $6.7 Billion
May 14, 2024 10:09 ET
|
Research and Markets
Dublin, May 14, 2024 (GLOBE NEWSWIRE) -- The "Iron Drugs - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.Global Iron Drugs Market to Reach $11 Billion...